Published in J Immunol on October 01, 1978
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med (1985) 3.56
Depressed primary in vitro antibody response in untreated systemic lupus erythematosus. T helper cell defect and lack of defective suppressor cell function. J Clin Invest (1980) 1.68
The suppressive effect of M. leprae on the in vitro proliferative responses of lymphocytes from patients with leprosy. Clin Exp Immunol (1980) 1.42
Autoantibody to an immunoregulatory inducer population in patients with juvenile rheumatoid arthritis. J Clin Invest (1981) 1.37
Enumeration of T lymphocytes subsets in autoimmune disease using monoclonal antibodies. Clin Exp Immunol (1981) 1.34
Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol (1981) 1.32
Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies, and T cell functions. J Clin Invest (1984) 1.32
Aberrant immunoregulatory control of B lymphocyte function in lepromatous leprosy. Clin Exp Immunol (1982) 1.30
Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis (1992) 1.20
Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J Clin Invest (1985) 1.18
Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. J Clin Invest (1990) 1.17
Defective B cell function in systemic lupus erythematosus. Clin Exp Immunol (1982) 1.13
Characteristics and function of Fc receptors on human lymphocytes. Immunology (1982) 1.09
Z-DNA-specific antibodies in human systemic lupus erythematosus. J Clin Invest (1983) 1.09
Studies of immune functions of patients with systemic lupus erythematosus. T-cell subsets and antibodies to T-cell subsets. J Clin Invest (1979) 1.09
Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol (1994) 1.09
Alterations in T lymphocytes and T-lymphocyte subpopulations in patients with syphilis. Br J Vener Dis (1982) 1.07
Autoimmune diseases: immunopathology and etiopathogenesis. Am J Pathol (1982) 1.07
Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (1988) 1.07
Immunoglobulin production in vitro by peripheral blood lymphocytes in systemic lupus erythematosus: helper T cell defect and B cell hyperreactivity. Clin Exp Immunol (1981) 1.05
Immunoregulation in glomerulonephritis, Henoch--Schonlein purpura and lupus nephritis. Clin Exp Immunol (1983) 1.04
Animal models of human systemic lupus erythematosus. Yale J Biol Med (1979) 1.02
Anaplastic myeloma in systemic lupus erythematosus. Ann Rheum Dis (1984) 1.02
Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest (1994) 1.01
Antibodies to T cells in patients with systemic lupus erythematosus can induce antibody-dependent cell-mediated cytotoxicity against human T cells. J Clin Invest (1981) 1.00
Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1982) 0.99
Altered cellular immunity and suppressor cell activity in patients with primary retinitis pigmentosa. Br J Ophthalmol (1981) 0.98
The in vitro production and regulation of anti-double stranded DNA antibodies by peripheral blood mononuclear cells from normals and patients with systemic lupus erythematosus. Clin Exp Immunol (1984) 0.97
Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol (1990) 0.96
Immunoregulation in Sjögren's syndrome: influence of serum factors on T-cell subpopulations. J Clin Invest (1980) 0.96
Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol (1992) 0.96
Impaired antigen-specific suppressor cell activity in patients with systemic lupus erythematosus. Clin Exp Immunol (1980) 0.95
Suppressor cell function in a family with familial Mediterranean fever. Clin Exp Immunol (1981) 0.95
Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol (1984) 0.94
Relationship between T cell subpopulations and the mitogen responsiveness and suppressor cell function of peripheral blood mononuclear cells in normal individuals. Clin Exp Immunol (1980) 0.93
Diminished synthesis of immunoglobulin by peripheral lymphocytes of patients with idiopathic membranous glomerulonephropathy. J Clin Invest (1980) 0.93
Inhibition of soluble antigen-induced T cell proliferation by warm-reactive antibodies to activated T cells in systemic lupus erythematosus. J Clin Invest (1984) 0.92
Extrathyroidal sites of autoantibody synthesis in Graves' disease. Clin Exp Immunol (1984) 0.91
Impaired antibody-dependent cell-mediated cytotoxicity in cryptogenic fibrosing alveolitis (synonym: idiopathic pulmonary fibrosis). Clin Exp Immunol (1982) 0.89
In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis (1988) 0.88
T lymphocyte interaction with immunoglobulin G antibody in systemic lupus erythematosus. J Clin Invest (1982) 0.87
Impaired T cell capping and receptor regeneration in active systemic lupus erythematosus. Evidence for a disorder intrinsic to the T lymphocyte. J Clin Invest (1983) 0.87
Induction of excessive B cell proliferation and differentiation by an in vitro stimulus in culture in human systemic lupus erythematosus. J Clin Invest (1989) 0.87
Studies of immune functions of patients with systemic lupus erythematosus: antibodies to desialized, rather than intact, T cells preferentially bind to and eliminate suppressor effector T cells. J Clin Invest (1982) 0.87
Impaired autologous mixed-lymphocyte reaction of peripheral blood lymphocytes in adult periodontitis. Infect Immun (1991) 0.86
Spontaneous and Concanavalin A-induced suppressor activity in control and Hodgkin's disease patients. Br J Cancer (1984) 0.86
Detection of antilymphocyte antibody with two-color method in systemic lupus erythematosus and its heterogeneous specificities against human T-cell subsets. J Clin Invest (1979) 0.86
Functional heterogeneities among concanavalin A-activated OKT4+ and OKT8+ cells by using autologous erythrocyte rosette technique. J Clin Invest (1983) 0.85
Mononuclear phagocytes from patients with active systemic lupus erythematosus down-regulate the specific in vitro reactivity of autologous lymphocytes to double-stranded DNA. Clin Exp Immunol (1988) 0.84
Immunoregulation and anti-nuclear antibodies in mercury-induced glomerulopathy in the rat. Clin Exp Immunol (1981) 0.84
T cell function in systemic lupus erythematosus: normal production of and responsiveness to interleukin 2. Clin Exp Immunol (1986) 0.84
The in vitro production of anti-nuclear antibodies by human peripheral blood mononuclear cells. Demonstration of T cell requirement and soluble inducing factor(s) for anti-nuclear antibodies triggering in patients with systemic lupus erythematosus. Clin Exp Immunol (1984) 0.83
Functional activity of peripheral mononuclear cells in cystic fibrosis: antibodies and plaque formation. Clin Exp Immunol (1982) 0.82
Analysis of T-lymphocyte subpopulations in juvenile-onset diabetics. Clin Exp Immunol (1980) 0.81
Production of migration inhibition factor (MIF) by purified human T cell subpopulations. Clin Exp Immunol (1981) 0.81
Depletion of lymphocytes with membrane markers of helper phenotype: a feature of acute and chronic drug-induced immunosuppression. Clin Exp Immunol (1983) 0.81
Suppression of DNA synthesis by con A-activated human lymphocytes: role of monocytes in con A-induced suppression. Clin Exp Immunol (1980) 0.80
Spontaneous immunoglobulin A secretion and lack of mitogen-responsive B cells in systemic lupus erythematosus. J Clin Invest (1985) 0.80
Production of a suppressor factor by human adherent cells treated with Mycobacterium tuberculosis: absence in systemic lupus erythematosus. Clin Exp Immunol (1981) 0.79
Infection of multiple T-cell subsets and changes in lymphocyte functions associated with Herpesvirus saimiri infection of owl monkeys. Infect Immun (1981) 0.79
Suppressor response in lepromatous leprosy patients: role of Leu 2a cells. Immunology (1987) 0.78
Studies on human blood lymphocytes with iC3b (type 3) complement receptors: III. Abnormalities in patients with active systemic lupus erythematosus. Clin Exp Immunol (1987) 0.78
Human B cell function in responder and non-responder individuals. II. The role of T helper cells in promoting the PWM-induced B cell production of immunoprotein. Clin Exp Immunol (1983) 0.78
Systemic lupus erythematosus and invasive thymoma: report of two cases. Ann Rheum Dis (1984) 0.77
Immunoglobulin production after marrow transplantation. III. The functional heterogeneity of FC-IgG receptor positive and negative T cell subpopulations. Clin Exp Immunol (1982) 0.77
T cell subpopulations in inflammatory bowel disease: evidence for a defective induction of T8+ suppressor/cytotoxic T lymphocytes. Clin Exp Immunol (1985) 0.75
Subpopulations of T lymphocytes in patients with ankylosing spondylitis. Ann Rheum Dis (1980) 0.75
Diseases associated with immunosuppression. Environ Health Perspect (1982) 0.75
OKT4+ T cell deficiency and an association of immunoglobulin deficiency in systemic lupus erythematosus. Clin Exp Immunol (1988) 0.75
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 13.32
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum (1990) 8.23
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Takayasu arteritis. Ann Intern Med (1994) 5.94
A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity (1996) 5.64
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci U S A (1984) 5.15
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A (1989) 4.22
HIV. An elusive soluble suppressor. Nature (1995) 4.18
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol (1974) 3.98
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med (1975) 3.70
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol (1991) 3.04
X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J Exp Med (1975) 3.03
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00
The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain. J Immunol (1973) 3.00
CD44--a molecule involved in leukocyte adherence and T-cell activation. Immunol Today (1989) 2.96
Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1978) 2.94
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature (1997) 2.94
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science (1994) 2.92
Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol (1980) 2.89
The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med (1990) 2.82
Decline in suppressor T cell function with age in female NZB mice. J Immunol (1974) 2.79
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med (1985) 2.77
Activation of human B lymphocytes. I. Direct plaque-forming cell assay for the measurement of polyclonal activation and antigenic stimulation of human B lymphocytes. J Exp Med (1976) 2.75
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
NIH conference. The acquired immunodeficiency syndrome: an update. Ann Intern Med (1985) 2.68
Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med (1990) 2.65
Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol (1989) 2.62